Mohammed Moursi
Concepts (314)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Endarterectomy, Carotid | 13 | 2017 | 63 | 2.640 |
Why?
| | Tunica Intima | 11 | 2011 | 55 | 2.430 |
Why?
| | Vascular Surgical Procedures | 7 | 2018 | 171 | 1.810 |
Why?
| | Endovascular Procedures | 8 | 2025 | 193 | 1.780 |
Why?
| | Blood Vessel Prosthesis Implantation | 6 | 2025 | 135 | 1.360 |
Why?
| | Homocysteine | 8 | 2011 | 127 | 1.350 |
Why?
| | Carotid Stenosis | 5 | 2017 | 65 | 1.250 |
Why?
| | Carotid Arteries | 5 | 2010 | 77 | 1.080 |
Why?
| | Vascular Diseases | 2 | 2018 | 75 | 1.030 |
Why?
| | Aortic Aneurysm, Abdominal | 5 | 2019 | 52 | 1.000 |
Why?
| | Aortic Aneurysm, Thoracic | 1 | 2025 | 28 | 0.930 |
Why?
| | Carotid Artery, Common | 4 | 2011 | 45 | 0.900 |
Why?
| | Platelet Aggregation Inhibitors | 4 | 2006 | 213 | 0.760 |
Why?
| | Hyperplasia | 11 | 2011 | 98 | 0.740 |
Why?
| | Arterial Occlusive Diseases | 9 | 2017 | 85 | 0.680 |
Why?
| | Time Factors | 16 | 2025 | 2991 | 0.600 |
Why?
| | Certification | 1 | 2018 | 52 | 0.550 |
Why?
| | Rats, Sprague-Dawley | 12 | 2011 | 1544 | 0.530 |
Why?
| | Rats | 14 | 2011 | 3162 | 0.520 |
Why?
| | Risk Reduction Behavior | 1 | 2017 | 58 | 0.520 |
Why?
| | Catheterization, Peripheral | 3 | 2024 | 49 | 0.450 |
Why?
| | Insulin Resistance | 2 | 2010 | 282 | 0.450 |
Why?
| | Tobacco Use Disorder | 1 | 2017 | 174 | 0.450 |
Why?
| | Male | 36 | 2025 | 27435 | 0.450 |
Why?
| | Pediatrics | 1 | 2018 | 307 | 0.450 |
Why?
| | Ticlopidine | 2 | 2006 | 71 | 0.440 |
Why?
| | Receptors, N-Methyl-D-Aspartate | 2 | 2005 | 79 | 0.440 |
Why?
| | Iliac Aneurysm | 1 | 2014 | 11 | 0.430 |
Why?
| | Smoking | 2 | 2017 | 526 | 0.430 |
Why?
| | Salivary Proteins and Peptides | 2 | 2004 | 8 | 0.430 |
Why?
| | Pelvis | 1 | 2014 | 66 | 0.420 |
Why?
| | Hemostatic Techniques | 5 | 2017 | 32 | 0.420 |
Why?
| | Smoking Cessation | 1 | 2017 | 325 | 0.410 |
Why?
| | Treatment Outcome | 17 | 2025 | 5595 | 0.400 |
Why?
| | Patient Acceptance of Health Care | 1 | 2017 | 379 | 0.400 |
Why?
| | Internship and Residency | 1 | 2018 | 439 | 0.390 |
Why?
| | Risk Factors | 10 | 2025 | 4017 | 0.390 |
Why?
| | Muscle, Smooth, Vascular | 3 | 2005 | 135 | 0.390 |
Why?
| | Disease Models, Animal | 7 | 2011 | 1517 | 0.380 |
Why?
| | Postoperative Complications | 8 | 2025 | 1099 | 0.380 |
Why?
| | Age Factors | 5 | 2025 | 1136 | 0.370 |
Why?
| | Carotid Artery Injuries | 1 | 2011 | 12 | 0.360 |
Why?
| | Femoral Artery | 5 | 2016 | 106 | 0.330 |
Why?
| | Acarbose | 1 | 2010 | 2 | 0.330 |
Why?
| | Estradiol | 1 | 2011 | 215 | 0.320 |
Why?
| | Animals | 17 | 2011 | 13526 | 0.310 |
Why?
| | Female | 25 | 2025 | 28782 | 0.310 |
Why?
| | Comorbidity | 4 | 2025 | 638 | 0.300 |
Why?
| | Aged | 17 | 2025 | 10429 | 0.300 |
Why?
| | Blood Vessel Prosthesis | 5 | 2019 | 89 | 0.300 |
Why?
| | Diet | 3 | 2008 | 610 | 0.290 |
Why?
| | Infant Food | 1 | 2008 | 28 | 0.290 |
Why?
| | Aorta | 3 | 2016 | 172 | 0.290 |
Why?
| | Middle Aged | 17 | 2025 | 13419 | 0.280 |
Why?
| | Hypoglycemic Agents | 1 | 2010 | 227 | 0.280 |
Why?
| | Ketorolac Tromethamine | 1 | 2007 | 3 | 0.270 |
Why?
| | Humans | 32 | 2025 | 53230 | 0.270 |
Why?
| | Myocytes, Smooth Muscle | 2 | 2005 | 96 | 0.270 |
Why?
| | Cyclooxygenase Inhibitors | 1 | 2007 | 40 | 0.270 |
Why?
| | Thrombosis | 2 | 2017 | 250 | 0.270 |
Why?
| | Retrospective Studies | 14 | 2025 | 6819 | 0.270 |
Why?
| | Risk Assessment | 4 | 2025 | 1368 | 0.250 |
Why?
| | Patient Discharge | 2 | 2019 | 325 | 0.240 |
Why?
| | Pravastatin | 1 | 2006 | 18 | 0.240 |
Why?
| | Erythrocyte Transfusion | 1 | 2025 | 53 | 0.230 |
Why?
| | Hyperhomocysteinemia | 2 | 2011 | 29 | 0.230 |
Why?
| | Antioxidants | 1 | 2007 | 264 | 0.230 |
Why?
| | Arteries | 2 | 2017 | 93 | 0.230 |
Why?
| | Aorta, Abdominal | 3 | 2019 | 39 | 0.230 |
Why?
| | Anemia | 1 | 2025 | 76 | 0.230 |
Why?
| | Surgical Procedures, Operative | 1 | 2025 | 66 | 0.220 |
Why?
| | Postoperative Care | 1 | 2025 | 109 | 0.220 |
Why?
| | Catheterization | 2 | 2024 | 95 | 0.220 |
Why?
| | Device Removal | 2 | 2024 | 89 | 0.220 |
Why?
| | Ischemia | 4 | 2008 | 158 | 0.220 |
Why?
| | Blood Platelets | 2 | 2006 | 247 | 0.220 |
Why?
| | Renal Dialysis | 2 | 2003 | 196 | 0.220 |
Why?
| | Smoke | 1 | 2004 | 18 | 0.220 |
Why?
| | Platelet Aggregation | 1 | 2005 | 77 | 0.220 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2006 | 146 | 0.210 |
Why?
| | Cell Division | 1 | 2005 | 289 | 0.210 |
Why?
| | Folic Acid | 2 | 2003 | 137 | 0.210 |
Why?
| | Vascular System Injuries | 1 | 2024 | 42 | 0.210 |
Why?
| | Hospitals, Veterans | 1 | 2003 | 107 | 0.200 |
Why?
| | Endothelium, Vascular | 1 | 2005 | 262 | 0.200 |
Why?
| | Stents | 4 | 2019 | 376 | 0.200 |
Why?
| | Albumins | 1 | 2003 | 29 | 0.200 |
Why?
| | Ultrasonic Therapy | 1 | 2003 | 30 | 0.200 |
Why?
| | Oxidative Stress | 1 | 2007 | 819 | 0.190 |
Why?
| | Disease Progression | 1 | 2025 | 880 | 0.190 |
Why?
| | Punctures | 6 | 2017 | 52 | 0.190 |
Why?
| | Arteriovenous Shunt, Surgical | 1 | 2003 | 35 | 0.190 |
Why?
| | Femoral Vein | 2 | 2015 | 39 | 0.190 |
Why?
| | Arkansas | 6 | 2017 | 2068 | 0.180 |
Why?
| | Fluorocarbons | 1 | 2003 | 65 | 0.180 |
Why?
| | Collagen | 1 | 2003 | 215 | 0.180 |
Why?
| | Contrast Media | 1 | 2003 | 178 | 0.180 |
Why?
| | Fibrinolytic Agents | 2 | 2017 | 132 | 0.170 |
Why?
| | Extracorporeal Membrane Oxygenation | 1 | 2024 | 305 | 0.170 |
Why?
| | Prosthesis-Related Infections | 2 | 2016 | 109 | 0.170 |
Why?
| | Wounds, Nonpenetrating | 2 | 2016 | 86 | 0.170 |
Why?
| | Angioplasty, Balloon | 2 | 2007 | 69 | 0.170 |
Why?
| | Length of Stay | 3 | 2019 | 684 | 0.170 |
Why?
| | Blue Toe Syndrome | 1 | 2000 | 3 | 0.160 |
Why?
| | Recurrence | 3 | 2017 | 694 | 0.160 |
Why?
| | Models, Animal | 3 | 2006 | 233 | 0.160 |
Why?
| | Methylenetetrahydrofolate Reductase (NADPH2) | 3 | 2004 | 58 | 0.160 |
Why?
| | Angiography | 3 | 2017 | 114 | 0.150 |
Why?
| | Adult | 9 | 2025 | 14534 | 0.150 |
Why?
| | Hospital Costs | 1 | 2019 | 74 | 0.150 |
Why?
| | Vascular Patency | 6 | 2015 | 88 | 0.150 |
Why?
| | Cardiac Catheterization | 2 | 2001 | 229 | 0.140 |
Why?
| | Clinical Competence | 2 | 2018 | 406 | 0.140 |
Why?
| | Wound Infection | 2 | 2016 | 33 | 0.140 |
Why?
| | Health Care Surveys | 1 | 2018 | 182 | 0.140 |
Why?
| | Equipment Design | 5 | 2017 | 290 | 0.140 |
Why?
| | Thrombolytic Therapy | 2 | 2017 | 114 | 0.130 |
Why?
| | Dietary Supplements | 1 | 2001 | 479 | 0.130 |
Why?
| | Dietary Sucrose | 2 | 2010 | 14 | 0.130 |
Why?
| | Mechanical Thrombolysis | 1 | 2017 | 8 | 0.130 |
Why?
| | Hospitals, Pediatric | 1 | 2018 | 243 | 0.130 |
Why?
| | Postoperative Hemorrhage | 1 | 2017 | 54 | 0.130 |
Why?
| | Blood Loss, Surgical | 1 | 2017 | 66 | 0.130 |
Why?
| | Behavior, Addictive | 1 | 2017 | 62 | 0.130 |
Why?
| | Mentors | 1 | 2017 | 57 | 0.130 |
Why?
| | Immunohistochemistry | 3 | 2005 | 975 | 0.120 |
Why?
| | Venous Thrombosis | 1 | 2017 | 91 | 0.120 |
Why?
| | Thoracic Injuries | 1 | 2016 | 36 | 0.120 |
Why?
| | Hypertension | 1 | 2001 | 554 | 0.120 |
Why?
| | Collateral Circulation | 2 | 2008 | 39 | 0.110 |
Why?
| | Surgical Flaps | 1 | 2016 | 110 | 0.110 |
Why?
| | Aortic Diseases | 1 | 2015 | 54 | 0.110 |
Why?
| | Attitude of Health Personnel | 1 | 2018 | 371 | 0.110 |
Why?
| | Education, Medical, Graduate | 1 | 2017 | 219 | 0.110 |
Why?
| | Cystathionine beta-Synthase | 2 | 2004 | 20 | 0.110 |
Why?
| | Insulin | 2 | 2010 | 493 | 0.110 |
Why?
| | International Normalized Ratio | 1 | 2014 | 29 | 0.110 |
Why?
| | Leg | 3 | 2007 | 123 | 0.110 |
Why?
| | Angioplasty | 2 | 2011 | 21 | 0.110 |
Why?
| | Tomography, X-Ray Computed | 3 | 2016 | 1180 | 0.100 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2018 | 523 | 0.100 |
Why?
| | Blood Coagulation | 1 | 2014 | 65 | 0.100 |
Why?
| | Practice Guidelines as Topic | 3 | 2025 | 502 | 0.100 |
Why?
| | Dogs | 3 | 2003 | 186 | 0.100 |
Why?
| | Reoperation | 4 | 2015 | 476 | 0.100 |
Why?
| | Random Allocation | 2 | 2004 | 284 | 0.100 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2007 | 1367 | 0.100 |
Why?
| | Registries | 4 | 2019 | 652 | 0.090 |
Why?
| | Myocardial Infarction | 3 | 2025 | 445 | 0.090 |
Why?
| | Acute Kidney Injury | 1 | 2017 | 399 | 0.090 |
Why?
| | Regional Blood Flow | 2 | 2010 | 112 | 0.090 |
Why?
| | Infusion Pumps, Implantable | 1 | 2011 | 15 | 0.090 |
Why?
| | Estrogen Replacement Therapy | 1 | 2011 | 28 | 0.090 |
Why?
| | Jugular Veins | 1 | 2011 | 29 | 0.090 |
Why?
| | Kaplan-Meier Estimate | 3 | 2019 | 487 | 0.090 |
Why?
| | Ovariectomy | 1 | 2011 | 114 | 0.090 |
Why?
| | Multivariate Analysis | 3 | 2017 | 598 | 0.090 |
Why?
| | Anticoagulants | 1 | 2014 | 280 | 0.090 |
Why?
| | Odds Ratio | 3 | 2017 | 567 | 0.080 |
Why?
| | Radial Artery | 1 | 2011 | 34 | 0.080 |
Why?
| | Ultrasonography, Doppler, Pulsed | 1 | 2010 | 2 | 0.080 |
Why?
| | Survival Rate | 3 | 2016 | 949 | 0.080 |
Why?
| | Saphenous Vein | 1 | 2011 | 63 | 0.080 |
Why?
| | Blood Flow Velocity | 1 | 2010 | 99 | 0.080 |
Why?
| | Recovery of Function | 2 | 2017 | 203 | 0.080 |
Why?
| | Hemorrhage | 2 | 2014 | 226 | 0.080 |
Why?
| | Aged, 80 and over | 4 | 2019 | 3494 | 0.080 |
Why?
| | Logistic Models | 3 | 2017 | 947 | 0.080 |
Why?
| | Coronary Artery Bypass | 1 | 2011 | 134 | 0.080 |
Why?
| | United States | 4 | 2019 | 5409 | 0.080 |
Why?
| | Follow-Up Studies | 4 | 2019 | 2318 | 0.070 |
Why?
| | Madagascar | 1 | 2008 | 3 | 0.070 |
Why?
| | Celiac Artery | 1 | 2008 | 8 | 0.070 |
Why?
| | Popliteal Vein | 1 | 2008 | 14 | 0.070 |
Why?
| | Ligaments | 1 | 2008 | 12 | 0.070 |
Why?
| | Angiography, Digital Subtraction | 1 | 2008 | 28 | 0.070 |
Why?
| | Infant Nutritional Physiological Phenomena | 1 | 2008 | 62 | 0.070 |
Why?
| | Eating | 1 | 2008 | 159 | 0.070 |
Why?
| | Vasodilator Agents | 1 | 2008 | 90 | 0.070 |
Why?
| | Malondialdehyde | 1 | 2007 | 55 | 0.070 |
Why?
| | Endarterectomy | 1 | 2007 | 10 | 0.070 |
Why?
| | Blood Glucose | 1 | 2010 | 490 | 0.070 |
Why?
| | Platelet Activation | 1 | 2007 | 48 | 0.070 |
Why?
| | Severity of Illness Index | 2 | 2007 | 1049 | 0.060 |
Why?
| | Graft Occlusion, Vascular | 2 | 2007 | 81 | 0.060 |
Why?
| | Coronary Artery Disease | 1 | 2011 | 324 | 0.060 |
Why?
| | Abdominal Injuries | 1 | 2006 | 35 | 0.060 |
Why?
| | Breast Feeding | 1 | 2008 | 203 | 0.060 |
Why?
| | Glutathione | 1 | 2007 | 303 | 0.060 |
Why?
| | Constriction | 2 | 2004 | 8 | 0.060 |
Why?
| | Limb Salvage | 2 | 2016 | 43 | 0.060 |
Why?
| | Single-Blind Method | 1 | 2025 | 120 | 0.060 |
Why?
| | Drug Combinations | 1 | 2006 | 138 | 0.060 |
Why?
| | Dizocilpine Maleate | 1 | 2005 | 14 | 0.060 |
Why?
| | Interleukin-1 | 1 | 2005 | 103 | 0.060 |
Why?
| | Cholesterol | 1 | 2006 | 161 | 0.060 |
Why?
| | Matrix Metalloproteinase 9 | 1 | 2005 | 88 | 0.060 |
Why?
| | Hemoglobins | 1 | 2025 | 114 | 0.060 |
Why?
| | DNA, Complementary | 1 | 2005 | 128 | 0.060 |
Why?
| | Homocystine | 1 | 2004 | 8 | 0.060 |
Why?
| | Cell Count | 1 | 2005 | 141 | 0.060 |
Why?
| | Excitatory Amino Acid Antagonists | 1 | 2005 | 46 | 0.060 |
Why?
| | C-Reactive Protein | 1 | 2006 | 152 | 0.060 |
Why?
| | Platelet Function Tests | 1 | 2004 | 22 | 0.060 |
Why?
| | Cell Culture Techniques | 1 | 2005 | 99 | 0.060 |
Why?
| | Aorta, Thoracic | 1 | 2005 | 101 | 0.050 |
Why?
| | Lower Extremity | 1 | 2005 | 103 | 0.050 |
Why?
| | Cotinine | 1 | 2004 | 20 | 0.050 |
Why?
| | Probability | 1 | 2004 | 171 | 0.050 |
Why?
| | Patient Selection | 2 | 2017 | 273 | 0.050 |
Why?
| | Constriction, Pathologic | 2 | 2008 | 91 | 0.050 |
Why?
| | Reference Values | 1 | 2004 | 311 | 0.050 |
Why?
| | Biopsy, Needle | 1 | 2004 | 181 | 0.050 |
Why?
| | Cell Movement | 1 | 2005 | 279 | 0.050 |
Why?
| | RNA | 1 | 2005 | 173 | 0.050 |
Why?
| | Arginine | 1 | 2005 | 178 | 0.050 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2005 | 579 | 0.050 |
Why?
| | Blotting, Western | 1 | 2005 | 587 | 0.050 |
Why?
| | Nitric Oxide | 1 | 2005 | 233 | 0.050 |
Why?
| | Platelet Adhesiveness | 1 | 2003 | 15 | 0.050 |
Why?
| | Cystathionine gamma-Lyase | 1 | 2003 | 6 | 0.050 |
Why?
| | Oxidoreductases Acting on CH-NH Group Donors | 1 | 2003 | 16 | 0.050 |
Why?
| | Analysis of Variance | 1 | 2004 | 547 | 0.050 |
Why?
| | Polytetrafluoroethylene | 1 | 2003 | 33 | 0.050 |
Why?
| | Elastin | 1 | 2003 | 24 | 0.050 |
Why?
| | Hospital Mortality | 1 | 2025 | 457 | 0.050 |
Why?
| | Anastomosis, Surgical | 1 | 2003 | 69 | 0.050 |
Why?
| | Microspheres | 1 | 2003 | 19 | 0.050 |
Why?
| | Dietary Carbohydrates | 1 | 2003 | 91 | 0.050 |
Why?
| | Gene Expression | 1 | 2005 | 618 | 0.050 |
Why?
| | Equipment Failure | 2 | 2017 | 64 | 0.050 |
Why?
| | Extracellular Matrix | 1 | 2003 | 116 | 0.050 |
Why?
| | Dietary Fats | 1 | 2003 | 133 | 0.050 |
Why?
| | Sensitivity and Specificity | 1 | 2004 | 867 | 0.050 |
Why?
| | Feasibility Studies | 2 | 2017 | 411 | 0.050 |
Why?
| | United States Department of Veterans Affairs | 1 | 2003 | 295 | 0.050 |
Why?
| | RNA, Messenger | 1 | 2005 | 1133 | 0.040 |
Why?
| | Cells, Cultured | 1 | 2005 | 1569 | 0.040 |
Why?
| | Cell Proliferation | 1 | 2005 | 1031 | 0.040 |
Why?
| | Models, Cardiovascular | 1 | 2001 | 22 | 0.040 |
Why?
| | Groin | 2 | 2016 | 16 | 0.040 |
Why?
| | Rats, Inbred SHR | 1 | 2001 | 42 | 0.040 |
Why?
| | Epigastric Arteries | 1 | 2000 | 2 | 0.040 |
Why?
| | Abdominal Muscles | 1 | 2000 | 12 | 0.040 |
Why?
| | Staining and Labeling | 1 | 2001 | 94 | 0.040 |
Why?
| | Embolism | 1 | 2000 | 18 | 0.040 |
Why?
| | Actins | 1 | 2001 | 114 | 0.040 |
Why?
| | Pneumonia | 1 | 2001 | 123 | 0.040 |
Why?
| | Models, Biological | 1 | 2003 | 737 | 0.040 |
Why?
| | Infant | 1 | 2008 | 3805 | 0.040 |
Why?
| | Survival Analysis | 1 | 2001 | 659 | 0.040 |
Why?
| | Radiography, Interventional | 1 | 2000 | 58 | 0.040 |
Why?
| | Retreatment | 1 | 2019 | 60 | 0.040 |
Why?
| | United States Food and Drug Administration | 1 | 1999 | 93 | 0.040 |
Why?
| | Cost Savings | 1 | 2019 | 60 | 0.040 |
Why?
| | Operative Time | 1 | 2019 | 78 | 0.040 |
Why?
| | Stroke | 2 | 2017 | 520 | 0.040 |
Why?
| | Predictive Value of Tests | 2 | 2014 | 934 | 0.040 |
Why?
| | Cause of Death | 1 | 2019 | 156 | 0.040 |
Why?
| | Cost-Benefit Analysis | 1 | 2019 | 274 | 0.040 |
Why?
| | Postoperative Period | 1 | 1998 | 169 | 0.030 |
Why?
| | Prosthesis Design | 1 | 2019 | 266 | 0.030 |
Why?
| | Linear Models | 1 | 1998 | 287 | 0.030 |
Why?
| | Critical Care | 1 | 2019 | 215 | 0.030 |
Why?
| | Social Networking | 1 | 2017 | 19 | 0.030 |
Why?
| | Blindness | 1 | 2017 | 33 | 0.030 |
Why?
| | Young Adult | 2 | 2017 | 4511 | 0.030 |
Why?
| | Patient Readmission | 1 | 2019 | 251 | 0.030 |
Why?
| | Infant, Newborn | 1 | 2024 | 2913 | 0.030 |
Why?
| | Ischemic Attack, Transient | 1 | 2017 | 59 | 0.030 |
Why?
| | Watchful Waiting | 1 | 2016 | 29 | 0.030 |
Why?
| | Interpersonal Relations | 1 | 2017 | 116 | 0.030 |
Why?
| | Tertiary Care Centers | 1 | 2016 | 86 | 0.030 |
Why?
| | Tissue and Organ Harvesting | 1 | 2015 | 25 | 0.030 |
Why?
| | Chi-Square Distribution | 1 | 2016 | 291 | 0.030 |
Why?
| | Heart Failure | 1 | 2001 | 531 | 0.030 |
Why?
| | Treatment Failure | 1 | 2015 | 119 | 0.030 |
Why?
| | Internet | 1 | 2017 | 265 | 0.030 |
Why?
| | Trauma Centers | 1 | 2016 | 210 | 0.030 |
Why?
| | Academic Medical Centers | 1 | 2015 | 153 | 0.030 |
Why?
| | Sex Factors | 1 | 2017 | 747 | 0.030 |
Why?
| | Wound Healing | 1 | 2016 | 226 | 0.030 |
Why?
| | Vascular Access Devices | 1 | 2014 | 23 | 0.030 |
Why?
| | Curriculum | 1 | 2017 | 409 | 0.030 |
Why?
| | Biomedical Research | 1 | 2017 | 267 | 0.030 |
Why?
| | Databases, Factual | 1 | 2017 | 742 | 0.030 |
Why?
| | Ultrasonography, Interventional | 1 | 2014 | 138 | 0.020 |
Why?
| | Child | 1 | 2024 | 7379 | 0.020 |
Why?
| | Prospective Studies | 1 | 2017 | 2411 | 0.020 |
Why?
| | Adolescent | 2 | 2017 | 6907 | 0.020 |
Why?
| | Myocardial Revascularization | 1 | 2011 | 29 | 0.020 |
Why?
| | Coronary Angiography | 1 | 2011 | 369 | 0.020 |
Why?
| | Injections, Intra-Arterial | 1 | 2008 | 14 | 0.020 |
Why?
| | Mesenteric Artery, Superior | 1 | 2008 | 12 | 0.020 |
Why?
| | Hypoxanthines | 1 | 1988 | 1 | 0.020 |
Why?
| | Inosine | 1 | 1988 | 2 | 0.020 |
Why?
| | Xanthines | 1 | 1988 | 8 | 0.020 |
Why?
| | Renal Circulation | 1 | 1988 | 57 | 0.020 |
Why?
| | Syndrome | 1 | 2008 | 248 | 0.020 |
Why?
| | Adenosine | 1 | 1988 | 72 | 0.020 |
Why?
| | Alloys | 1 | 2007 | 10 | 0.020 |
Why?
| | Image Enhancement | 1 | 2007 | 49 | 0.020 |
Why?
| | Arteriovenous Fistula | 1 | 2006 | 28 | 0.020 |
Why?
| | Aneurysm, False | 1 | 2006 | 44 | 0.020 |
Why?
| | Infusions, Intra-Arterial | 1 | 2005 | 13 | 0.010 |
Why?
| | Blood Pressure | 1 | 1988 | 518 | 0.010 |
Why?
| | Ultrasonography | 1 | 2006 | 426 | 0.010 |
Why?
| | Diagnosis, Differential | 1 | 2006 | 1038 | 0.010 |
Why?
| | Xanthine | 1 | 1988 | 1 | 0.000 |
Why?
| | Phentolamine | 1 | 1988 | 7 | 0.000 |
Why?
| | Hypoxanthine | 1 | 1988 | 5 | 0.000 |
Why?
| | Receptors, Adrenergic, alpha | 1 | 1988 | 15 | 0.000 |
Why?
| | Adrenergic alpha-Antagonists | 1 | 1988 | 27 | 0.000 |
Why?
| | Adenosine Triphosphate | 1 | 1988 | 211 | 0.000 |
Why?
|
|
Moursi's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
|